Navigation Links
ArmaGen Announces Strategic Licensing and Collaboration Agreement with Shire to Develop AGT-182 for Treatment of Hunter Syndrome
Date:7/23/2014

vancing ArmaGen's proprietary pipeline of innovative therapies."

"Our agreement with ArmaGen strengthens our long-standing commitment to the Hunter syndrome community to bring forward novel therapies that have the potential to dramatically redefine the treatment paradigm and address the most critical unmet needs," said Philip J. Vickers, Ph.D., Global Head of Research and Development at Shire. "AGT-182 has the potential to be an important new therapy to our existing portfolio of Hunter syndrome programs. We plan to apply our proven ability to develop therapies for rare genetic diseases to progress AGT-182 as a potential treatment that offers hope to patients with Hunter syndrome and their families."

About Hunter Syndrome

Hunter syndrome, also known as mucopolysaccharidosis type II, or MPS II, is a lysosomal storage disorder caused by inadequate activity of the enzyme iduronate-2-sulfatase (IDS), which is needed to break down complex sugars produced by the body. The buildup of these complex sugars, known as mucopolysaccharides, interferes with functioning of certain cells and organs, leading to serious complications including developmental delays and mental impairment. Symptoms of Hunter syndrome include growth delay, joint stiffness and coarsening of facial features. In severe cases, patients experience respiratory and cardiac problems, enlargement of the liver and spleen, and neurological deficits that can lead to premature death. Hunter syndrome primarily affects males and is almost always severe, progressive and life-limiting. Available treatments for Hunter syndrome are not expected to cross the blood-brain barrier (BBB) in clinically relevant amounts and therefore do not address the progressive neurological complications of the disease.

About AGT-182 

AGT-182 is a novel, investigational ERT that has received orphan drug designation from both the U.S. Food and Drug Administration (FDA) and the
'/>"/>

SOURCE ArmaGen
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmagen Partners with Bagel Boy Equity Group II, LLC and prepares to Launch its Industry Consolidation Strategy
2. Pharmagen Announces Food and Drug Administration Registration
3. Pharmagen Announces Shift In Growth Strategy
4. CoMentis and Anvyl Announce Formation of Alpharmagen, a Joint Venture to explore Nicotinic Modulators
5. Pharmagen Announces First Quarter 2013 Results
6. Pharmagen to Present Strategic Vision for Solving Nations Parenteral Drug Shortage Crisis at 2013 BIO International Convention
7. Pharmagen Laboratories Remains Industry Leader on Patient Safety
8. Pharmagen Presents to North Carolina General Assembly at N.C. Bios Legislative Breakfast
9. Pharmagen Announces Year-End Financial Results
10. Galmed Announces FDA Clearance of IND of Armachol for the Treatment of Fatty Liver Disorders
11. Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 XBiotech announced ... study in patients with moderate to severe plaque ... open-label Phase II trial evaluated the potential benefit ... that targets interleukin-1 alpha (IL-1a). IL-1a is a ... present in skin lesions. The Company claims that ...
(Date:3/4/2015)... , March 4, 2015   Aratana Therapeutics, Inc ... company focused on the licensing, development and commercialization of ... it will present at the Barclays Global Healthcare ... the Loews Miami Beach Hotel in Miami ... Peter , M.D., President and Chief Executive Officer of ...
(Date:3/4/2015)... -- Following the reintroduction of the Comprehensive Addiction ... a report today urging policymakers to take steps ... through more effective use of medication-assisted treatment (MAT).  ... Expanding Access to Medication-Assisted Treatment to Address the ... and economic advantages of medication-assisted treatment along with ...
Breaking Medicine Technology:XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2Aratana Therapeutics to Present at the Barclays Global Healthcare Conference 2Improved Medication-Assisted Treatment Policy Could Aid Epidemic of 20 Million Americans with Untreated Addiction 2
... According to an overview of industry data released ... , in Fiscal Year 2011, pharmaceutical companies continued a ... delay the introduction of lower-cost prescription drug alternatives for ... that drug companies entered into 28 potential pay-for-delay ...
... ABAXIS, Inc. (NasdaqGS: ABAX), a medical products company manufacturing ... the second fiscal quarter ended September 30, 2011. ... $40.0 million, up 13% over last year,s comparable quarter. ... over last year,s comparable quarter. Veterinary market sales ...
Cached Medicine Technology:FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 2FTC Study Finds that in FY 2011, Pharmaceutical Industry Continued to Make Numerous Business Deals that Delay Consumers' Access to Lower-Cost Generic Drugs 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 2Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 3Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 4Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 5Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 6Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 7Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 8Abaxis Reports Financial Performance with Record Revenues for the Second Quarter of Fiscal 2012 9
(Date:3/4/2015)... (PRWEB) March 04, 2015 FDA’s New ... , **FDAnews Webinar**, March 24, 2015 — 1:30 p.m. ... investigators generally know within four hours of an inspection ... manufacturer is on their “good” list, they’ll merely ask ... a manufacturer is on the “bad” list, the manufacturer ...
(Date:3/4/2015)... The ability of volumetric breast ... and help improve breast cancer risk prediction models ... presentation at the European Congress of Radiology (ECR) ... eight posters and 2 session presentations - highlight ... and quantitative breast imaging software tools to provide ...
(Date:3/4/2015)... With the growing influence of movies, television, video games and ... adults, combined with the increasingly frantic lifestyle of modern parents, ... up with what kids are into these days. It seems ... daily basis. , The same is also true for drugs ... to discreetly talk about them, are constantly changing. These tips ...
(Date:3/4/2015)... York, New York (PRWEB) March 04, 2015 ... was reviewing the cardiovascular risks potentially associated with low ... Drug Administration (FDA) announced that it will now require ... may increase their risk for heart attacks and strokes. ... 3, 2015, the agency also stated that it was ...
(Date:3/4/2015)... Vancouver chiropractic clinic, Backs in Action ... the prestigious Vancouver Courier “Stars of Vancouver” 2015 ... company secured third place in the “Best Chiropractor” ... Massage Therapist” category. , As one of ... Vancouver Courier is a semiweekly local newspaper published ...
Breaking Medicine News(10 mins):Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4Health News:Backs in Action Receives Two Awards in The Vancouver Courier Readers’ Choice Awards 2015 2
... some experts, newly born neuronal stem cells in the adult ... these stem cells are to be utilized in this way, ... regulated. , A new study, led by Laurence Katz, ... of the North Carolina School of Medicine, suggests a way ...
... FALLS" , A study by Indiana University ... of their elderly study participants and their postural stability ... in line with recent findings by other researchers involving ... designed to probe cognitive function effective at identifying people ...
... of American,Physicians, Inc. (CAP) today announced that the exceptional ... has again,earned an A+ rating from A.M. Best Company, ... consecutive year that MPT has,achieved this rating., "We ... Rating again this year,",said CEO James L. Weidner. "It ...
... to millions of diabetics who are missed , , FRIDAY, ... for diabetes is being called for to help the ... disease, a new report says. , "Approximately 30 percent ... undiagnosed," study author Dr. Christopher Saudek, of Johns Hopkins ...
... & Asthma Network Mothers of Asthmatics Applauds FDA Public ... and Offers Critical Facts Patients Need to Know, ... their healthcare providers do not know that at the ... Today, FDA urged patients,still using chlorofluorocarbon (CFC) albuterol metered-dose ...
... EXTON, Pa., May 30 Isolagen(TM), Inc. (Amex:,ILE) ... notice from the staff,of the American Stock Exchange (AMEX) ... compliance did not demonstrate its ability,to regain compliance with ... (a)(i)-(iii) of the AMEX Company Guide within the,prescribed time ...
Cached Medicine News:Health News:Indiana University research at the American College of Sports Medicine annual conference 2Health News:Indiana University research at the American College of Sports Medicine annual conference 3Health News:Indiana University research at the American College of Sports Medicine annual conference 4Health News:Indiana University research at the American College of Sports Medicine annual conference 5Health News:Indiana University research at the American College of Sports Medicine annual conference 6Health News:Indiana University research at the American College of Sports Medicine annual conference 7Health News:Mutual Protection Trust Earns Third A+ Rating From A.M. Best 2Health News:Panel Calls for Better Diabetes Screening 2Health News:Get the Facts on the Albuterol Inhaler Transition 2Health News:Get the Facts on the Albuterol Inhaler Transition 3Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 2Health News:Isolagen, Inc. Reports Receipt of Initiation of Delisting Proceedings Notice from Amex 3
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems...
The Uromac Petite data processor, transducers and Powerbook® computer can be disassembled quickly and easily for travel to multiple sites, providing a very flexible and portable urodynamics syste...
... by Laborie, a leading producer ... credible tracings. ICS recognized Urodynamics ... parameters. Designed especially for the ... to be quick, efficient and ...
... offers ultimate flexibility by allowing you to ... and display. Wall-mount anywhere in the room. ... a laptop, touch screen tablet, industrial PC, ... this multi-function patient tower provides more power ...
Medicine Products: